Nurix Therapeutics, Inc. (NRIX)
NRIX Stock Price Chart
Explore Nurix Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze NRIX price movements and trends.
NRIX Company Profile
Discover essential business fundamentals and corporate details for Nurix Therapeutics, Inc. (NRIX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Jul 2020
Employees
314.00
Website
https://www.nurixtx.comCEO
Arthur T. Sands
Description
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
NRIX Financial Timeline
Browse a chronological timeline of Nurix Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 8 Oct 2026
EPS estimate is -$0.66, while revenue estimate is $18.96m.
Earnings released on 9 Jul 2026
EPS came in at -$0.81 falling short of the estimated -$0.73 by -10.96%, while revenue for the quarter reached $9.04m , missing expectations by -40.85%.
Earnings released on 8 Apr 2026
EPS came in at -$0.79 falling short of the estimated -$0.76 by -3.95%, while revenue for the quarter reached $6.25m , missing expectations by -56.13%.
Earnings released on 28 Jan 2026
EPS came in at -$0.82 surpassing the estimated -$0.84 by +2.38%, while revenue for the quarter reached $13.58m , beating expectations by +1.33%.
Earnings released on 9 Oct 2025
EPS came in at -$1.03 falling short of the estimated -$0.84 by -22.62%, while revenue for the quarter reached $7.89m , missing expectations by -35.61%.
Earnings released on 9 Jul 2025
EPS came in at -$0.52 surpassing the estimated -$0.71 by +26.76%, while revenue for the quarter reached $44.06m , beating expectations by +151.56%.
Earnings released on 8 Apr 2025
EPS came in at -$0.67 surpassing the estimated -$0.72 by +6.94%, while revenue for the quarter reached $18.45m , beating expectations by +16.61%.
Earnings released on 28 Jan 2025
EPS came in at -$0.75 falling short of the estimated -$0.67 by -11.94%, while revenue for the quarter reached $13.28m , missing expectations by -10.11%.
Earnings released on 11 Oct 2024
EPS came in at -$0.67 matching the estimated -$0.67, while revenue for the quarter reached $12.59m , missing expectations by -1.73%.
Earnings released on 11 Jul 2024
EPS came in at -$0.71 falling short of the estimated -$0.66 by -7.58%, while revenue for the quarter reached $12.09m , missing expectations by -45.29%.
Earnings released on 10 Apr 2024
EPS came in at -$0.76 surpassing the estimated -$0.80 by +5.00%, while revenue for the quarter reached $16.59m , missing expectations by -4.13%.
Earnings released on 15 Feb 2024
EPS came in at -$0.77 falling short of the estimated -$0.51 by -50.98%, while revenue for the quarter reached $15.16m , missing expectations by -31.90%.
Earnings released on 12 Oct 2023
EPS came in at -$0.68 surpassing the estimated -$0.69 by +1.45%, while revenue for the quarter reached $18.47m , beating expectations by +15.56%.
Earnings released on 13 Jul 2023
EPS came in at -$0.45 surpassing the estimated -$0.63 by +28.57%, while revenue for the quarter reached $30.68m , beating expectations by +17.04%.
Earnings released on 13 Apr 2023
EPS came in at -$0.75 surpassing the estimated -$0.90 by +16.67%, while revenue for the quarter reached $12.69m , beating expectations by +16.70%.
Earnings released on 9 Feb 2023
EPS came in at -$0.87 falling short of the estimated -$0.68 by -27.94%, while revenue for the quarter reached $6.78m , missing expectations by -60.50%.
Earnings released on 6 Oct 2022
EPS came in at -$0.90 surpassing the estimated -$0.99 by +9.09%, while revenue for the quarter reached $10.79m , missing expectations by -10.61%.
Earnings released on 7 Jul 2022
EPS came in at -$1.01 falling short of the estimated -$1.00 by -1.00%, while revenue for the quarter reached $11.43m , beating expectations by +8.82%.
Earnings released on 7 Apr 2022
EPS came in at -$0.95 falling short of the estimated -$0.89 by -6.74%, while revenue for the quarter reached $9.62m , beating expectations by +3.75%.
Earnings released on 27 Jan 2022
EPS came in at -$0.85 falling short of the estimated -$0.67 by -26.87%, while revenue for the quarter reached $7.40m , missing expectations by -43.95%.
Earnings released on 14 Oct 2021
EPS came in at -$0.65 falling short of the estimated -$0.63 by -3.17%, while revenue for the quarter reached $10.25m , missing expectations by -1.49%.
NRIX Stock Performance
Access detailed NRIX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
